Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Smith

Showing results (91-100 of 168) with videos related to

Pageof 17
Sort By:
Cancer|July 23, 2008
Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancerCelestia S Higano, John M Corman, David C Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumorsTimothy D Gilligan, Jerome Seidenfeld, Ethan M Basch, et al.
Cancer|November 14, 2007
Randomized clinical trial of a family intervention for prostate cancer patients and their spousesLaurel L Northouse, Darlene W Mood, Ann Schafenacker, et al.
The Oncologist|March 18, 2016
Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid TumorsAnthony J Olszanski, David C Smith, Luis H Camacho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2017
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid TumorsAntonio Jimeno, Michael Gordon, Rashmi Chugh, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2017
A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinomaIgnace B Vergote, David C Smith, Raanan Berger, et al.
Cancer Chemotherapy and Pharmacology|February 27, 2015
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man studyHerbert I Hurwitz, David C Smith, Henry C Pitot, et al.
Urology|February 22, 2011
Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032David C Smith, Cathy M Tangen, Peter J Van Veldhuizen, et al.
The Science of the Total Environment|December 5, 2018
Impact of summer season on pre-hospital time delays in women and men undergoing primary percutaneous coronary interventionCaroline E Gebhard, Catherine Gebhard, Foued Maafi, et al.
Cancer|September 20, 2013
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials ConsortiumAndrea L Harzstark, Jonathan E Rosenberg, Vivian K Weinberg, et al.
Pageof 17

Showing results (91-100 of 168) with videos related to

Sort By:
Pageof 17
Cancer|July 23, 2008
Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancerCelestia S Higano, John M Corman, David C Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumorsTimothy D Gilligan, Jerome Seidenfeld, Ethan M Basch, et al.
Cancer|November 14, 2007
Randomized clinical trial of a family intervention for prostate cancer patients and their spousesLaurel L Northouse, Darlene W Mood, Ann Schafenacker, et al.
The Oncologist|March 18, 2016
Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid TumorsAnthony J Olszanski, David C Smith, Luis H Camacho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2017
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid TumorsAntonio Jimeno, Michael Gordon, Rashmi Chugh, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2017
A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinomaIgnace B Vergote, David C Smith, Raanan Berger, et al.
Cancer Chemotherapy and Pharmacology|February 27, 2015
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man studyHerbert I Hurwitz, David C Smith, Henry C Pitot, et al.
Urology|February 22, 2011
Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032David C Smith, Cathy M Tangen, Peter J Van Veldhuizen, et al.
The Science of the Total Environment|December 5, 2018
Impact of summer season on pre-hospital time delays in women and men undergoing primary percutaneous coronary interventionCaroline E Gebhard, Catherine Gebhard, Foued Maafi, et al.
Cancer|September 20, 2013
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials ConsortiumAndrea L Harzstark, Jonathan E Rosenberg, Vivian K Weinberg, et al.
Pageof 17